Capital Management Corp VA Boosts Holdings in Lifevantage Corporation $LFVN

Capital Management Corp VA grew its position in shares of Lifevantage Corporation (NASDAQ:LFVN) by 63.0% in the third quarter, Holdings Channel reports. The firm owned 2,064,176 shares of the company’s stock after purchasing an additional 798,066 shares during the period. Lifevantage comprises approximately 3.2% of Capital Management Corp VA’s holdings, making the stock its 11th biggest position. Capital Management Corp VA owned 0.16% of Lifevantage worth $20,084,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in LFVN. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Lifevantage during the second quarter valued at $784,000. Los Angeles Capital Management LLC purchased a new stake in shares of Lifevantage in the 2nd quarter valued at about $288,000. AlphaQuest LLC boosted its position in shares of Lifevantage by 12,659.7% during the 2nd quarter. AlphaQuest LLC now owns 7,911 shares of the company’s stock valued at $103,000 after acquiring an additional 7,849 shares during the last quarter. Farther Finance Advisors LLC purchased a new position in shares of Lifevantage during the second quarter worth about $25,000. Finally, JPMorgan Chase & Co. increased its position in shares of Lifevantage by 870.2% in the second quarter. JPMorgan Chase & Co. now owns 5,016 shares of the company’s stock worth $66,000 after purchasing an additional 4,499 shares during the last quarter. Hedge funds and other institutional investors own 35.32% of the company’s stock.

Lifevantage Stock Performance

Shares of LFVN opened at $5.30 on Friday. Lifevantage Corporation has a fifty-two week low of $5.15 and a fifty-two week high of $24.06. The firm has a market cap of $67.31 million, a price-to-earnings ratio of 6.88 and a beta of 0.34. The firm has a 50 day moving average price of $6.30 and a 200-day moving average price of $9.12.

Lifevantage (NASDAQ:LFVN) last released its earnings results on Tuesday, November 4th. The company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.17 by $0.01. The company had revenue of $47.56 million for the quarter, compared to analyst estimates of $54.74 million. Lifevantage had a net margin of 4.43% and a return on equity of 33.52%. Lifevantage has set its FY 2026 guidance at 1.000-1.150 EPS.

Insider Activity at Lifevantage

In other news, Director Michael A. Beindorff sold 35,000 shares of the business’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $6.92, for a total value of $242,200.00. Following the completion of the sale, the director owned 56,413 shares of the company’s stock, valued at approximately $390,377.96. The trade was a 38.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold a total of 48,607 shares of company stock valued at $330,467 in the last quarter. 21.95% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Wall Street Zen lowered shares of Lifevantage from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lifevantage in a report on Monday, December 29th. Finally, Lake Street Capital reissued a “buy” rating and issued a $12.00 target price on shares of Lifevantage in a research note on Wednesday, November 5th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $12.00.

About Lifevantage

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.